Filter Results:
(4,369)
Show Results For
- All HBS Web
(4,369)
- People (14)
- News (1,532)
- Research (2,274)
- Events (1)
- Multimedia (155)
- Faculty Publications (1,786)
Show Results For
- All HBS Web
(4,369)
- People (14)
- News (1,532)
- Research (2,274)
- Events (1)
- Multimedia (155)
- Faculty Publications (1,786)
- 01 Feb 1997
- News
Herzlinger on Health Care: Revolution in Evolution
use expensive technology, which many people cite as the reason for high U.S. health-care costs? Actually,the opposite is true: advances in medical technology have made health care cheaper View Details
- 23 Feb 2017
- News
The power — and the fear — of knowing your cancer genome
- Article
Consumer-Driven Health Care: Freeing Providers to Innovate
Herzlinger, Regina E. "Consumer-Driven Health Care: Freeing Providers to Innovate." hfm (Healthcare Financial Management) 58, no. 3 (March 2004): 66–68.
- 01 Sep 2011
- News
Student Trio Advance Health Payment Reform
quality of care. Traditionally, doctors and hospitals have been paid separate fees for their services, an approach widely criticized for rewarding overuse of diagnostic tests and procedures while providing... View Details
- Article
Managing Healthcare Costs and Value
By: Robert S. Kaplan, Michael E. Porter and Mark L. Frigo
Rising health care costs are a major global challenge. A number of factors contribute to this trend, including aging populations and medical technology. But an underlying and misunderstood source of health care’s escalating costs has been the inability of health care... View Details
Kaplan, Robert S., Michael E. Porter, and Mark L. Frigo. "Managing Healthcare Costs and Value." Strategic Finance 98, no. 7 (January 2017): 24–33.
- November 2012 (Revised June 2014)
- Case
Boston Children's Hospital: Measuring Patient Costs (V)
By: Robert S. Kaplan, Mary L. Witkowski and Jessica A. Hohman
Keywords: Health Care; Time-Driven Activity-Based Costing; Costing; Hospitals; Activity Based Costing and Management
Kaplan, Robert S., Mary L. Witkowski, and Jessica A. Hohman. "Boston Children's Hospital: Measuring Patient Costs (V)." Harvard Business School Case 113-057, November 2012. (Revised June 2014.)
- 2023
- Working Paper
Achieving Universal Health Insurance Coverage in the United States: Addressing Market Failures or Providing a Social Floor?
By: Katherine Baicker, Amitabh Chandra and Mark Shepard
The United States spends substantially more on health care than most developed countries, yet leaves a greater share of the population uninsured. We suggest that incremental insurance expansions focused on addressing market failures will propagate inefficiencies and... View Details
Baicker, Katherine, Amitabh Chandra, and Mark Shepard. "Achieving Universal Health Insurance Coverage in the United States: Addressing Market Failures or Providing a Social Floor?" NBER Working Paper Series, No. 30854, January 2023.
- June 2014 (Revised April 2015)
- Supplement
OrthoChoice: Bundled Payments in the County of Stockholm (B)
By: Michael E. Porter, Clifford M. Marks and Zachary C. Landman
By the end of 2008, all major hospitals (one of which was private) and three private specialized orthopedic centers signed OrthoChoice contracts. In 2009, hip and knee replacements in the County of Stockholm for relatively healthy patients began being reimbursed. By... View Details
Keywords: Hip Replacement; Bundled Payment; Knee Replacement; Value Agenda; Strategy; Health Care Industry; Health; Health Care and Treatment; Health Disorders; Health Industry; Sweden
Porter, Michael E., Clifford M. Marks, and Zachary C. Landman. "OrthoChoice: Bundled Payments in the County of Stockholm (B)." Harvard Business School Supplement 714-515, June 2014. (Revised April 2015.)
- 29 Aug 2016
- News
Health Insurers’ Pullback Threatens to Create Monopolies
- September 2013
- Supplement
John G. Meara, Boston Children's Hospital, Measuring Costs, TDABC
By: Robert S. Kaplan
Keywords: Health Care; Time-Driven Activity-Based Costing; Costing; Hospitals; Activity Based Costing and Management
Kaplan, Robert S. "John G. Meara, Boston Children's Hospital, Measuring Costs, TDABC." Harvard Business School Video Supplement 114-702, September 2013.
- 01 Dec 2007
- News
Where Are the Innovators in Health Care?
of pages of regulations. Time and again the regulatory status quo blocks entrepreneurship. No wonder the twenty or so doctors enrolled in my Innovating in Health Care course at... View Details
- 28 Nov 2016
- News
What’s good for employee health is good for the company
- January 1978
- Case
Zero-Base Budgeting in the Public Health Service
Herzlinger, Regina E. "Zero-Base Budgeting in the Public Health Service." Harvard Business School Case 178-080, January 1978.
- 18 Oct 2016
- News
Why Business Should Invest in Community Health
- January 2019
- Teaching Note
Pricing PatientPing
By: Frank V. Cespedes
Teaching Note for HBS No. 818-017. PatientPing sells a software platform that allows health care providers to receive real-time notifications (“pings”) when one of their patients is admitted to or discharged from a health-care facility. The platform facilitates... View Details
- 05 Sep 2013
- News
Who Will Radically Disrupt American Health Care?
- 15 Dec 2024
- News
Agenda: Amanda E/J Morrison (MBA 2014)
RIPPLE EFFECT “A woman gets a period around age 12 to 14, and then we tell her to go off in the world and not get pregnant.” “A woman gets a period around age 12 to 14, and then we tell her to go off in the world and not get pregnant.” For 15 years, the morning-after... View Details
- November 2016
- Case
QuintilesIMS: Biosimilar Marketing in England
By: John A. Quelch and Emily C. Boudreau
QuintilesIMS was a leading healthcare consulting firm best known for its data and information offerings as well as its market research and management consulting services for life science companies. By 2015, the company was expanding beyond the biopharmaceutical... View Details
Keywords: Health; Pharmaceutical Industry; Biotech; Marketing; Health Care and Treatment; Biotechnology Industry; England
Quelch, John A., and Emily C. Boudreau. "QuintilesIMS: Biosimilar Marketing in England." Harvard Business School Case 517-054, November 2016.
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details
Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "The Impact of the Entry of Biosimilars: Evidence from Europe." Review of Industrial Organization 53, no. 1 (August 2018): 173–210.